Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Iterum Therapeutics plcDecember 21, 2020 GMT
DUBLIN, Ireland and CHICAGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that on December 18, 2020, the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) approved the Company’s request to transfer its listing to The Nasdaq Capital Market from The Nasdaq Global Market. The transfer is expected to take effect at the opening of business on Wednesday, December 23, 2020. The Company’s shares will continue to trade under the symbol “ITRM.” The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Market, and listed companies must meet certain financial and corporate governance requirements.